JPS56167617A - Permeation device - Google Patents

Permeation device

Info

Publication number
JPS56167617A
JPS56167617A JP6154181A JP6154181A JPS56167617A JP S56167617 A JPS56167617 A JP S56167617A JP 6154181 A JP6154181 A JP 6154181A JP 6154181 A JP6154181 A JP 6154181A JP S56167617 A JPS56167617 A JP S56167617A
Authority
JP
Japan
Prior art keywords
active agent
compartment
dispensing
fluid
permeation device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6154181A
Other languages
English (en)
Japanese (ja)
Other versions
JPH044293B2 (enExample
Inventor
Bonsen Piitaa
Setsukuurai Uongu Patoritsuku
Seeuesu Fueritsukusu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of JPS56167617A publication Critical patent/JPS56167617A/ja
Publication of JPH044293B2 publication Critical patent/JPH044293B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP6154181A 1980-04-25 1981-04-24 Permeation device Granted JPS56167617A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/143,644 US4265874A (en) 1980-04-25 1980-04-25 Method of delivering drug with aid of effervescent activity generated in environment of use

Publications (2)

Publication Number Publication Date
JPS56167617A true JPS56167617A (en) 1981-12-23
JPH044293B2 JPH044293B2 (enExample) 1992-01-27

Family

ID=22504961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6154181A Granted JPS56167617A (en) 1980-04-25 1981-04-24 Permeation device

Country Status (11)

Country Link
US (1) US4265874A (enExample)
EP (1) EP0040899B1 (enExample)
JP (1) JPS56167617A (enExample)
AT (1) ATE9267T1 (enExample)
DE (1) DE3165901D1 (enExample)
DK (1) DK152482C (enExample)
ES (2) ES267593Y (enExample)
GR (1) GR73519B (enExample)
IE (1) IE51216B1 (enExample)
NZ (1) NZ196561A (enExample)
PT (1) PT72796B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153214A (ja) * 1983-08-16 1986-03-17 ザ　ウエルカム　フアウンデ−シヨン　リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
US6639485B2 (en) 1999-12-09 2003-10-28 Murata Manufacturing Co., Ltd. Nonreciprocal circuit device and communication device using same
US6861922B2 (en) 2000-03-02 2005-03-01 Murata Manufacturing Co., Ltd. Nonreciprocal circuit device including two series resonant circuits having differing resonant frequencies
JP2018508941A (ja) * 2015-01-21 2018-03-29 ロッキード・マーティン・アドバンスト・エナジー・ストレージ・エルエルシーＬｏｃｋｈｅｅｄ Ｍａｒｔｉｎ Ａｄｖａｎｃｅｄ Ｅｎｅｒｇｙ Ｓｔｏｒａｇｅ， ＬＬＣ 電解液用の固体緩衝物質及びそれを利用したフロー電池

Families Citing this family (734)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
US4478596A (en) * 1982-11-26 1984-10-23 Michelson Paul E Delivery system for physiologically active agents
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4670578A (en) * 1983-08-29 1987-06-02 Merck & Co., Inc. Process for crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters
EP0137364A3 (en) * 1983-09-23 1986-10-22 Merck & Co. Inc. Suppository form of an osmotic therapeutic system
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
GB2150434B (en) * 1983-12-01 1987-11-04 Alza Corp Constant rate release systems
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US4595583A (en) * 1984-03-19 1986-06-17 Alza Corporation Delivery system controlled administration of beneficial agent to ruminants
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
EP0166354B1 (en) 1984-06-26 1992-08-05 Merck & Co. Inc. Benzofused lactam compounds and pharmaceutical compositions containing them
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
US4847093A (en) * 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5143908A (en) * 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US4715994A (en) * 1986-11-05 1987-12-29 Merck & Co., Inc. Novel antibacterial agents and potentiators of carbapenem antibiotics
US5099063A (en) * 1986-11-05 1992-03-24 Merck & Co., Inc. Certain phosphinic acid derivatives having antibacterial activity
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5499979A (en) * 1987-06-25 1996-03-19 Alza Corporation Delivery system comprising kinetic forces
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
JPS6413097A (en) * 1987-07-06 1989-01-17 Mitsubishi Chem Ind Phosphonic acid derivative
US5041644A (en) * 1987-07-06 1991-08-20 Merck & Co., Inc. Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
DE3873278T2 (de) 1987-09-22 1993-02-25 Merck & Co Inc Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
US5030732A (en) * 1988-03-03 1991-07-09 Merck & Co., Inc. Aminoethylphosphinic acid derivatives
CH675537A5 (enExample) * 1988-03-25 1990-10-15 Ciba Geigy Ag
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
US5147867A (en) * 1988-10-28 1992-09-15 Merck & Co., Inc. Phosphorus containing enzyme inhibitors
US4962097A (en) * 1988-10-28 1990-10-09 Merck & Co., Inc. Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
US5145990A (en) * 1988-10-28 1992-09-08 Merck & Co., Inc. Phosphorous containing dhp enzyme inhibitors
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5089530A (en) 1990-08-03 1992-02-18 Merck & Co., Inc. Novel fermentation product with antiparasitic activity
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5639782A (en) * 1992-03-04 1997-06-17 Center For Innovative Technology Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
US5463083A (en) 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
AU666578B2 (en) 1992-07-13 1996-02-15 Cytomed, Inc 2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5750565A (en) * 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6348571B1 (en) 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JPH11505258A (ja) * 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5756540A (en) * 1995-06-02 1998-05-26 Mcw Research Foundation, Inc. Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US6372713B1 (en) 1995-09-08 2002-04-16 The Board Of Trustees Of Northwestern University Anti-depressant effects of corticotropin release inhibiting factor
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US5902605A (en) * 1996-04-18 1999-05-11 Alza Corporation Drug delivery device with minimal residual drug retention
US5785688A (en) * 1996-05-07 1998-07-28 Ceramatec, Inc. Fluid delivery apparatus and method
US5939460A (en) * 1996-07-08 1999-08-17 Idun Pharmaceuticals, Inc. Method of inhibiting NADPH oxidase
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
WO1998011066A1 (en) 1996-09-10 1998-03-19 Medinox, Inc. Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications
US5858402A (en) * 1997-02-11 1999-01-12 Medinox, Inc. Methods for in vivo reduction of cyanide levels and compositions useful therefor
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5985592A (en) * 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US7105496B2 (en) * 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
US6358536B1 (en) 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6750201B1 (en) * 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6984773B1 (en) * 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
US6756491B2 (en) 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
CA2289621A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase)
US6287605B1 (en) * 1998-04-17 2001-09-11 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treatment and prevention of HIV-1 infection
AU3979099A (en) 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
US6333318B1 (en) * 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US20030064917A1 (en) * 1998-07-23 2003-04-03 Crawford Susan E. Methods and compositions for inhibiting angiogenesis
AU5561999A (en) 1998-08-13 2000-03-06 Wistar Institute, The Methods for reducing atherosclerotic plaques
US6565854B2 (en) 1998-08-13 2003-05-20 Philadelphia Health And Education Corporation Antimicrobial histone H1 compositions, kits, and methods of use thereof
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US20020138856A1 (en) * 1998-10-23 2002-09-26 Northwestern University Compositions and methods useful for treatment of depressive disorder based on an animal model
CN100374163C (zh) 1999-01-13 2008-03-12 阿尔凯米亚肿瘤学私人有限公司 增强药物功效的组合物
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US7282489B2 (en) * 2000-01-19 2007-10-16 The Children's Hospital Of Philadelphia Compositions and methods for performing reverse gene therapy
WO2000041731A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Reverse gene therapy
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
US6221855B1 (en) 1999-03-11 2001-04-24 Wake Forest University Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
EP1180114B1 (en) 1999-04-27 2011-09-21 The Trustees of The University of Pennsylvania Use of resisitin specific antibodies in the treatment of diabetes
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US7033780B1 (en) * 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7160694B2 (en) 1999-06-14 2007-01-09 Millennium Pharmaceuticals, Inc. Nucleic acids encoding TANGO405 and functional fragments and uses thereof
US6964854B1 (en) * 1999-07-13 2005-11-15 Science & Technology Corporation Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
EP1221847B1 (en) 1999-10-08 2009-03-25 Taiji Biomedical, Inc. Methods of enhancing chemotherapy
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
EP1224222B1 (en) 1999-10-12 2010-02-10 ChemoCentryx Inc Chemokine receptor
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
US6559128B1 (en) 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US20030212021A1 (en) * 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
BR0109958A (pt) * 2000-04-07 2003-05-27 Univ Pennsylvania Análogos de didemnina e tamandarina e métodos de preparação e uso deles
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
ES2208595T3 (es) 2000-05-15 2004-06-16 Darwin Discovery Limited Derivados del acido hidroxamico.
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US7423177B2 (en) * 2001-03-05 2008-09-09 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
AU2001275043A1 (en) 2000-05-31 2001-12-11 Drugtech Corporation Mineral supplement
WO2001097752A2 (en) * 2000-06-20 2001-12-27 The Trustees Of The University Of Pennsylvania Compositions comprising urokinase for modulating muscle contractility and angiogenisis
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
EP1303536B1 (en) 2000-07-19 2010-03-17 Advanced Research And Technology Institute, Inc. Novel fibroblast growth factor (fgf23) and methods for use
WO2002019965A2 (en) * 2000-09-07 2002-03-14 Science & Technology Corporation @ Unm Heat shock response and virus replication
AU2001296915A1 (en) * 2000-09-26 2002-04-08 Sidney Kimmel Cancer Center Inhibition of antigen presentation with poorly catabolized polymers
US20040102367A1 (en) * 2001-02-23 2004-05-27 Gage Fred H Gene expression system based on chimeric receptors
JP2004523565A (ja) * 2001-03-05 2004-08-05 トランス　テック　ファーマ，インコーポレイテッド 治療因子としてのベンゾイミダゾール誘導体
AU2002248557A1 (en) * 2001-03-05 2002-09-19 Transtech Pharma, Inc. High level insect expression of rage proteins
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6727287B2 (en) 2001-04-16 2004-04-27 Pts International, Inc. Toluene sulfonamide-containing anti-tumor composition and method of use thereof
US6632217B2 (en) * 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
CN1157388C (zh) * 2001-05-29 2004-07-14 北京大学 哌嗪基二硫代甲酸酯类化合物,它们的制备方法和在抗肿瘤药物中的应用
RU2259825C9 (ru) 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
WO2003007793A2 (en) * 2001-07-17 2003-01-30 Yale University Compositions, methods, and kits related to treating and diagnosing hypertension
GB0119396D0 (en) * 2001-08-09 2001-10-03 Celltech R&D Ltd Hydroxamic acid derivatives
US9056048B2 (en) * 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
DE60236520D1 (de) * 2001-08-16 2010-07-08 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
WO2003018062A1 (en) * 2001-08-27 2003-03-06 Meditech Research Limited Improved therapeutic protocols
US20030069071A1 (en) * 2001-09-28 2003-04-10 Tim Britt Entertainment monitoring system and method
PL210841B1 (pl) * 2001-10-19 2012-03-30 Isotechnika Inc Sposób wytwarzania mieszaniny izomerów (E) i (Z) ISATX247
US6555563B1 (en) 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
UA84390C2 (ru) 2001-12-21 2008-10-27 Ново Нордиск А/Я Производные амидов как активаторы глюкокиназы
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
CA2476594C (en) * 2002-03-05 2012-10-09 Transtech Pharma, Inc. Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage
JP4570878B2 (ja) 2002-04-11 2010-10-27 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体モジュレーターとしての１Ｈ−ベンゾ［ｆ］インダゾール−５−イル誘導体
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
JP2005533013A (ja) * 2002-04-19 2005-11-04 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム 一酸化窒素供与基および反応性酸素種捕捉基を含有するβ作用薬化合物、ならびに呼吸障害の治療における該化合物の使用
US20030232741A1 (en) * 2002-05-06 2003-12-18 Washington University Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
AUPS234402A0 (en) * 2002-05-15 2002-06-13 Auckland Uniservices Limited Anti-tumour polycyclic carboxamides
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
JP4723242B2 (ja) 2002-06-12 2011-07-13 ケモセントリックス インコーポレーティッド 炎症および免疫障害治療用ｃｃｒ１アンタゴニストとして使用するための１−アリール−４−置換ピペラジン誘導体
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US6727241B2 (en) 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US20040077691A1 (en) * 2002-06-21 2004-04-22 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
US6620813B1 (en) 2002-06-21 2003-09-16 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
JP4881559B2 (ja) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
KR101122782B1 (ko) 2002-10-04 2012-04-12 프라나 바이오테크놀로지 리미티드 신경 활성 화합물
WO2004037206A2 (en) * 2002-10-23 2004-05-06 University Of Hawaii Methods for diagnosing and treating pre-term labor
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US7247725B2 (en) 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
ATE468114T1 (de) 2002-11-08 2010-06-15 High Point Pharmaceuticals Llc Sichere chemische entkuppler zur behandlung von fettsucht
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
PT1798223E (pt) * 2002-11-18 2011-10-17 Chemocentryx Inc Aril-sulfonamidas
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
NZ539952A (en) * 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
WO2004050084A2 (en) * 2002-11-29 2004-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
WO2004058705A2 (en) * 2002-12-20 2004-07-15 Chemocentryx Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor
NZ539488A (en) 2002-12-20 2008-03-28 Arakis Ltd Benzoxazocines and their use as monoamine-reuptake inhibitors
AU2004204751A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
AU2003900927A0 (en) * 2003-02-28 2003-03-13 Biodiem Ltd Growth promotion method
CA2519234A1 (en) * 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
MXPA05012350A (es) * 2003-05-20 2006-05-25 Transtech Pharma Inc Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma.
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
WO2005013907A2 (en) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2005014028A1 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
US8071535B2 (en) * 2003-09-12 2011-12-06 The Regents Of The University Of California Guanidinium derivatives for improved cellular transport
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
CA2539596A1 (en) 2003-09-30 2005-04-07 Kilian Waldemar Conde-Frieboes Melanocortin receptor agonists
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
CA2548105A1 (en) * 2003-12-12 2005-06-30 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
US8476455B2 (en) * 2003-12-15 2013-07-02 Laboratoire Theramex 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
CA2559211A1 (en) 2004-03-19 2005-09-29 Yale University Detection, isolation and uses of renalase (monoamine oxidase c)
CA2560528A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EP1737447A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
KR101258298B1 (ko) 2004-06-01 2013-04-25 유니버시티 오브 버지니아 페이턴트 파운데이션 암 및 혈관형성의 이중 소분자 억제제
JP2008502622A (ja) 2004-06-14 2008-01-31 サラマ，ゾーセル，ベー． プロリンまたはその誘導体および抗腫瘍抗体からなる抗癌組成物
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
EP1768992A1 (en) * 2004-06-24 2007-04-04 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
US8507411B2 (en) * 2004-06-24 2013-08-13 Wisconsin Alumni Research Foundation Neoglycorandomization and digitoxin analogs
ATE435853T1 (de) * 2004-07-02 2009-07-15 Allergan Inc Prostaglandinanaloga
AU2005271449A1 (en) * 2004-08-03 2006-02-16 The Trustees Of Columbia University In The City Of New York RAGE fusion proteins and methods of use
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7906552B2 (en) * 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
EP1784179A4 (en) 2004-08-24 2010-03-31 Merck Sharp & Dohme COMBINATION THERAPY FOR THE TREATMENT OF CYCLOOXYGENASE-2-MEDIATED DISEASES OR CONDITIONS IN PATIENTS WITH RISK TO THROMBOTIC CARDIOVASCULAR EVENTS
KR20070054246A (ko) 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 리소좀성 효소 결핍을 위한 조성물 및 이의 용도
CN101035537A (zh) * 2004-10-01 2007-09-12 默克公司 治疗眼部疾病的组合物和方法
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
US7612082B2 (en) * 2004-10-28 2009-11-03 Allergan, Inc. Prostaglandin EP4 antagonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
JP2008521864A (ja) 2004-12-03 2008-06-26 トランステック・ファーマ、インコーポレイテッド ヘテロ芳香族グルコキナーゼ活性化剤
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
AU2006204038A1 (en) * 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MX2007008474A (es) 2005-01-14 2008-02-19 Chemocentryx Inc Sulfonamidas de heteroarilo y ccr2.
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
TWI386208B (zh) * 2005-04-18 2013-02-21 Allergan Inc 治療性的經取代環戊酮
AU2006238855B2 (en) * 2005-04-21 2011-12-22 Chemocentryx, Inc. Reagents that bind CCX-CKR2
CN101166527A (zh) 2005-04-27 2008-04-23 艾尼纳制药公司 用于治疗肥胖症和糖尿病以及其相关病况和用于治疗可通过增加血液glp-1含量改善的病况的组合疗法
JP5254007B2 (ja) * 2005-05-06 2013-08-07 アラーガン インコーポレイテッド 置換β−ラクタム及び医薬におけるその使用
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
EP1883394B1 (en) 2005-05-23 2018-03-28 SDG, Inc. Lipid construct for delivery of insulin to a mammal
JP5225079B2 (ja) 2005-06-08 2013-07-03 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2612508A1 (en) * 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7799795B2 (en) 2005-06-27 2010-09-21 Amgen Inc. Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
WO2007005176A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
AU2006268589B2 (en) 2005-07-14 2011-09-29 Vtv Therapeutics Llc Urea glucokinase activators
JP5465431B2 (ja) * 2005-07-27 2014-04-09 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンを用いる治療プロトコル
CN101282962A (zh) 2005-08-12 2008-10-08 先灵公司 用于治疗炎性疾病的化合物
US20090035257A1 (en) 2005-08-25 2009-02-05 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
ATE520657T1 (de) * 2005-08-29 2011-09-15 Univ Virginia Patent Found Lisofyllin-analogika und ihre pharmazeutischen verwendungen
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
MY149606A (en) 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
AU2006306228A1 (en) * 2005-10-24 2007-05-03 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
ES2353549T3 (es) 2005-11-10 2011-03-03 Chemocentryx, Inc. Quinolonas sustituidas y métodos de uso.
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
EP1962840A1 (en) * 2005-12-20 2008-09-03 Gilead Colorado, Inc. Use of 4, 7-dihydrothieno [2, 3-b]pyridine compounds in the treatment of cardiovascular diseases
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
AU2007217500A1 (en) * 2006-02-21 2007-08-30 Astrum Therapeutics Pty. Ltd. Compositions to reduce blood glucose levels and treat diabetes
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
CA2645867A1 (en) 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
US20070225246A1 (en) * 2006-03-27 2007-09-27 Denu John M O-acetyl-ADP-ribose non-hydrolyzable analogs
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7833730B2 (en) * 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
CN101534826A (zh) 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7476755B2 (en) 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
MX2008014353A (es) 2006-05-09 2008-11-24 Merck & Co Inc Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos.
US7547727B2 (en) 2006-05-22 2009-06-16 Allergan, Inc. Therapeutic cyclopentane derivatives
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US7553860B2 (en) * 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
MX2008016411A (es) 2006-07-05 2009-04-28 Aventis Agriculture Compuestos derivados de 1-aril-5-alquil pirazol, procesos para hacerlos y metodos para usarlos.
WO2008008701A2 (en) 2006-07-10 2008-01-17 Allergan, Inc. Substituted cyclopentane derivatives as therapeutic agents
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EA015710B1 (ru) 2006-07-14 2011-10-31 Хемоцентрикс, Инк. Триазолил фенилбензолсульфонамиды
US7700627B2 (en) * 2006-07-26 2010-04-20 Allergan, Inc. Therapeutic substituted lactams
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US7985767B2 (en) * 2006-09-06 2011-07-26 Allergan, Inc. Therapeutic amides
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
WO2008067039A2 (en) * 2006-10-06 2008-06-05 Wisconsin Alumni Research Foundation Colchicine neoglycosides and methods for their synthesis and use
AU2007308154A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US8193373B2 (en) 2006-12-11 2012-06-05 Allergan, Inc. Therapeutic compounds
GB0624757D0 (en) 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
MX2009006672A (es) 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
AU2007337097A1 (en) 2006-12-22 2008-07-03 Allergan, Inc. Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
WO2008082217A1 (en) * 2006-12-28 2008-07-10 Lg Electronics Inc. Ice making system and method for ice making of refrigerator
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
EP2132183B1 (en) 2007-02-28 2015-06-03 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
US8563594B2 (en) * 2007-05-08 2013-10-22 Allergan, Inc. S1P3 receptor inhibitors for treating pain
ME03373B (me) 2007-05-15 2020-01-20 Merial Inc Ariloazol-2-il cijanoetilamino jedinjenja, postupci dobijanja i postupci njihove primene
US7629344B2 (en) 2007-05-22 2009-12-08 Chemocentryx, Inc. 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
WO2008156721A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Diphenyl substituted alkanes
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
CA2692761C (en) 2007-07-12 2013-04-30 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
WO2009012425A2 (en) * 2007-07-19 2009-01-22 Logigal Therapeutics, Inc. Compositions including leukotriene antagonists and nsaids and methods of using the same
US8222254B2 (en) 2007-08-07 2012-07-17 Prosarix Limited 1, 2, 4-triazole derivatives as serotonergic modulators
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
ES2447940T3 (es) 2007-10-15 2014-03-13 The Salk Institute For Biological Studies Métodos para el tratamiento de varias enfermedades y afecciones, y compuestos útiles para los mismos
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US20110160265A1 (en) * 2007-10-18 2011-06-30 Luhrs Lauren M B Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US8389485B2 (en) * 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
US20110009453A1 (en) * 2008-03-17 2011-01-13 Donello John E s1p3 receptor inhibitors for treating inflammation
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
UA103616C2 (ru) * 2008-04-24 2013-11-11 Аллерган, Инк. Замещенные гамма-лактамы как терапевтические агенты
WO2009132097A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2009131977A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Therapeutic compounds
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
WO2009137412A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
US7981887B2 (en) * 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
EP2285782A2 (en) * 2008-05-09 2011-02-23 Allergan, Inc. Therapeutic n-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives
US7786117B2 (en) * 2008-05-09 2010-08-31 Allergan, Inc. Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
WO2009137413A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic cyclopentane derivatives
CA2724972A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
CA2723894A1 (en) 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic substituted hydantoins, and related compounds
WO2009146255A1 (en) * 2008-05-27 2009-12-03 Allergan, Inc. Prostaglandin produgs as hypotensive agents
US8252788B2 (en) * 2008-05-20 2012-08-28 Allergan, Inc. Therapeutic compounds
CA2724467C (en) * 2008-05-20 2016-09-13 Allergan, Inc. Therapeutic lactams
WO2009152010A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. Branched 3- and 6-substituted quinolines as cgrp receptor antagonists
US8586607B2 (en) 2008-07-28 2013-11-19 Syddansk Universitet Compounds for the treatment of metabolic diseases
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
EP2186521A1 (en) 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
PT3050874T (pt) 2008-11-14 2019-05-09 Boehringer Ingelheim Animal Health Usa Inc Compostos parasiticidas de ariloazol-2-il-cianoetilamino enantiomericamente enriquecidos
SG171751A1 (en) 2008-11-19 2011-07-28 Merial Ltd Compositions comprising an aryl pyrazole and/ or a formamidine methods and uses thereof
EP2362730A4 (en) 2008-11-21 2012-08-29 High Point Pharmaceuticals Llc Adamantyl BENZAMIDE CONNECTIONS
EA019126B1 (ru) 2008-12-04 2014-01-30 Мериал Лимитед Димерные производные авермектина и милбемицина
DK2381778T3 (en) 2008-12-22 2016-09-12 Chemocentryx Inc C5aR antagonists
SI2565193T1 (sl) 2009-01-23 2014-07-31 Rigel Pharmaceuticals, Inc. Sestavki in metode inhibicije JAK poti
WO2010093849A2 (en) 2009-02-13 2010-08-19 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
JP2012518005A (ja) 2009-02-13 2012-08-09 アラーガン インコーポレイテッド ４‐（１‐（３‐（ヒドロキシメチル）‐２‐メチルフェニル）エチル）‐１ｈ‐イミダゾール‐２（３ｈ）‐チオン
CA2752148A1 (en) 2009-02-13 2010-08-19 Daniel W. Gil Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
KR101275980B1 (ko) 2009-02-24 2013-06-17 머크 캐나다 인크. Ｃｒｔｈ２ 수용체 길항제로서의 인돌 유도체
GB0904044D0 (en) 2009-03-09 2009-04-22 Sosei R & D Ltd The treatment of inflammatory disorders and pain
EP2406282A1 (en) 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
CA2757480A1 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP3195896A1 (en) 2009-05-05 2017-07-26 Board of Regents, The University of Texas System Novel formulations of volatile anesthetics and methods of use for reducing inflammation
SI2432454T1 (sl) 2009-05-19 2017-09-29 Neuroderm Ltd Sestavki za kontinuirano dajanje zaviralcev dopa-dekarboksilaze
DK2453890T3 (da) 2009-07-17 2020-08-17 Allergan Inc Sammensætninger omfattende en kolinesterase-inhibitor til behandling af kognitive lidelser
BR112012002001A2 (pt) * 2009-07-28 2016-05-10 Rigel Pharmaceuticals Inc método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit
RU2012105453A (ru) 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
TW201113525A (en) * 2009-08-20 2011-04-16 Anchen Lab Inc Methods for diagnosing diabetes and determining effectiveness of treatments
AU2010289703A1 (en) 2009-08-26 2012-04-12 Allergan, Inc. Method of treating compulsive disorders with alpha-2B adrenergic receptor agonists
CN102595897A (zh) 2009-09-02 2012-07-18 默沙东公司 作为用于糖尿病的治疗或预防的二肽基肽酶-iv抑制剂的氨基四氢吡喃
WO2011034951A2 (en) 2009-09-15 2011-03-24 The Regents Of The University Of California Assisted enzyme replacement therapy
CN102574789B (zh) 2009-09-21 2014-12-10 凯莫森特里克斯股份有限公司 吡咯烷酮甲酰胺衍生物作为趋化素-r(chemr23)调节剂
WO2011041198A1 (en) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Substituted imidazole derivatives for treatment of alzheimers disease
CA2781436C (en) 2009-11-25 2018-01-02 Cytometix, Inc. Arachidonic acid analogs and methods for analgesic treatment using same
NZ600252A (en) 2009-12-04 2014-03-28 Merial Ltd Pesticidal bis-organosulfur compounds
US8980896B2 (en) 2009-12-17 2015-03-17 Merial, Inc. Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
WO2011075591A1 (en) 2009-12-17 2011-06-23 Merial Limited Anti parasitic dihydroazole compounds and compositions comprising same
CN103664873B (zh) * 2009-12-30 2016-06-15 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
US9090584B2 (en) * 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
CA2788078A1 (en) 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusale M Ltd. Compositions and methods for prevention and treatment of pulmonary hypertension
US8299068B2 (en) 2010-01-29 2012-10-30 Allergan, Inc. Therapeutically active cyclopentanes
KR101791715B1 (ko) 2010-02-03 2017-10-30 파마 투 비 엘티디 라사길린의 연장 방출 제형 및 그 용도
GB201002530D0 (en) 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
WO2011103018A1 (en) 2010-02-18 2011-08-25 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
KR102113960B1 (ko) 2010-03-30 2020-05-21 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
UA108641C2 (uk) 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
CN103068390A (zh) 2010-04-20 2013-04-24 寰宇一家健康研究所 包含哒嗪磺酰胺衍生物的化合物、组合物和方法
US20110288103A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, compositions, and methods comprising 1,3,4-oxadiazole derivatives
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
MX347372B (es) 2010-05-26 2017-04-25 Vtv Therapeutics Llc Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
EP2582836B1 (en) 2010-06-18 2018-03-07 Taiho Pharmaceutical Co., Ltd. Prpk-tprkb modulators and uses thereof
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
US8859606B2 (en) 2010-07-01 2014-10-14 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US8492424B2 (en) 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
CA2804174A1 (en) 2010-07-02 2012-01-05 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
WO2012003145A2 (en) 2010-07-02 2012-01-05 Allergan, Inc. Therapeutic agents for ocular hypertension
US9714238B2 (en) 2010-07-02 2017-07-25 Allergan, Inc. Therapeutic agents for ocular hypertension
WO2012015972A1 (en) 2010-07-28 2012-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20130303497A1 (en) 2010-08-05 2013-11-14 Conrig Pharma Aps Deuterated 5-ht1a receptor agonists
CA2808307C (en) 2010-08-16 2022-06-21 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
PL2606044T3 (pl) 2010-08-20 2014-09-30 Allergan Inc Związki, które działają na wiele receptorów prostaglandyn, wywołujące ogólną odpowiedź przeciwzapalną
WO2012032513A1 (en) 2010-09-07 2012-03-15 Bar-Ilan University Boranophosphate derivatives for the treatment of osteoarthritis
WO2012032524A1 (en) 2010-09-09 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Near infrared fluorescent particles and uses thereof
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
BR112013009004B1 (pt) 2010-10-15 2022-05-10 Contera Pharma Aps Uso de composição farmacêutica ou kit de partes compreendendo combinações de agonistas dereceptor de serotonina
US20130315934A1 (en) 2010-10-28 2013-11-28 Yale University Methods and Compositions for Assessing and Treating Cancer
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
TWI487706B (zh) 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
NZ610911A (en) 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
DK2640728T3 (en) 2010-11-16 2016-11-28 Merial Inc NEW MONENSINDERIVATER FOR TREATMENT AND PREVENTION OF protozoal INFECTIONS
EP2643470B1 (en) 2010-11-24 2016-02-03 Yale University Compositions and methods for treating ischemic injury with d-dt
WO2012070040A1 (en) 2010-11-26 2012-05-31 Technion Research And Development Foundation Ltd Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
AU2011336973A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
GB201020860D0 (en) 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
SI2651965T1 (sl) 2010-12-15 2019-03-29 Contravir Pharmaceuticals, Inc. Analogne molekule ciklosporina, modificirane pri aminokislini 1 v 3
WO2012087777A1 (en) 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide cgrp receptor antagonists
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
CA2823397C (en) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
LT2683385T (lt) 2011-03-10 2018-10-25 Rigel Pharmaceuticals, Inc. 2,4 pakeistieji pirimidindiaminai, skirti naudoti sergant diskoidine vilklige
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
ES2543569T3 (es) 2011-03-23 2015-08-20 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
PH12013502075A1 (en) 2011-04-06 2018-03-21 Mcw Res Found Inc Epoxyeicosatrienoic acid analogs and methods of making and using the same
US9499467B2 (en) 2011-04-08 2016-11-22 Caldan Therapeutics Limited Ortho-fluoro substituted compounds for the treatment of metabolic diseases
US9480751B2 (en) 2011-04-11 2016-11-01 Yeda Research And Development Co. Ltd. Albumin binding probes and drug conjugates thereof
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US20140294957A1 (en) 2011-04-18 2014-10-02 Maxdelbruck-Centrum Fur Molekulare Medizin Niclosamide for the treatment of cancer metastasis
MX362218B (es) 2011-05-04 2019-01-09 Balance Therapeutics Inc Derivados de pentilentetrazol.
WO2012154809A1 (en) 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CA2837381C (en) 2011-05-27 2021-01-12 Allergan, Inc. D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders
WO2012163365A1 (en) 2011-06-01 2012-12-06 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
CA2839735A1 (en) 2011-06-17 2012-12-20 Yong-xin LI D-serine for the treatment of visual system disorders
AU2012275435B2 (en) 2011-06-27 2016-07-21 Boehringer Ingelheim Animal Health USA Inc. Amido-pyridyl ether compounds and compositions and their use against parasites
US20120329832A1 (en) 2011-06-27 2012-12-27 Jean Delaveau Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use
WO2013005216A1 (en) 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
US8513419B2 (en) 2011-07-25 2013-08-20 Allergan, Inc. N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors
US8609658B2 (en) 2011-07-27 2013-12-17 Allergan, Inc. N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
EP2763540A4 (en) 2011-09-09 2015-04-22 Univ Yale COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
AU2012312303B2 (en) 2011-09-22 2016-09-15 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
EP2763535B1 (en) 2011-10-03 2017-06-07 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
TWI619496B (zh) 2011-11-03 2018-04-01 台灣微脂體股份有限公司 疏水性喜樹鹼衍生物之醫藥組合物
EP2780008B1 (en) 2011-11-17 2017-07-05 Merial, Inc. Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof
TWI531366B (zh) 2011-11-18 2016-05-01 善笙生物科技股份有限公司 牛樟芝在關節炎、軟骨破壞或軟骨細胞死亡的改善或預防的功效
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
CA2856831C (en) 2011-12-01 2020-02-18 Chemocentryx, Inc. Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
MX358476B (es) 2011-12-02 2018-08-22 Merial Ltd Formulaciones de moxidectina inyectables de larga acción y formas de cristal de moxidectina novedosas.
US8993756B2 (en) 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
JP6124187B2 (ja) 2011-12-21 2017-05-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 一般的な抗炎症反応を与える複数のプロスタグランジン受容体において作用する化合物
US8969589B2 (en) 2011-12-21 2015-03-03 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2966064A1 (en) 2011-12-27 2016-01-13 Allergan, Inc. Pyrazole-3-carboxylic acid compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
US9035071B2 (en) 2011-12-27 2015-05-19 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
CN104349773A (zh) 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
EA201491335A1 (ru) 2012-01-06 2015-04-30 Элселикс Терапьютикс, Инк. Бигуанидные композиции и способы лечения метаболических расстройств
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
PT3263564T (pt) 2012-02-29 2020-09-10 Chemocentryx Inc Aza-aril 1h-pirazol-1-il benzeno sulfonamidas como antagonistas de ccr(9)
US8877967B2 (en) 2012-03-23 2014-11-04 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
WO2013155600A1 (en) 2012-04-16 2013-10-24 Kaneq Pharma Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
EP2838520B1 (en) 2012-04-17 2017-12-13 University College Dublin National University Of Ireland, Dublin Thromboxane receptor antagonists
US9718781B2 (en) 2012-04-17 2017-08-01 University College Dublin, National University Of Ireland, Dublin Methods and compounds for treating proliferative disorders and viral infections
NO2838517T3 (enExample) 2012-04-18 2018-03-17
WO2013169563A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
EP2846798B1 (en) 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
EP2846799B1 (en) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US20150368197A1 (en) 2012-06-21 2015-12-24 Radikal Therapeutics Ins. Compositions and methods for treatment of inflammatory diseases of the lung
EP2874622A4 (en) 2012-07-23 2015-12-30 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
US20140024621A1 (en) 2012-07-23 2014-01-23 Ms Therapeutics Limited Aminopyridine compounds and their uses
WO2014026013A2 (en) 2012-08-09 2014-02-13 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
WO2014043257A1 (en) 2012-09-12 2014-03-20 Rigel Pharmaceuticals, Inc. Treatment for vitiligo
RU2668791C2 (ru) 2012-10-19 2018-10-02 ТиЭксПи ФАРМА ГМБХ АНАЛОГИ АЛЬФА- и ГАММА-MSH
RU2661896C2 (ru) 2012-11-16 2018-07-23 Мерк Шарп И Доум Корп. Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека
HUE039915T2 (hu) 2012-11-20 2019-02-28 Merial Inc Anthelmintikus vegyületek és készítmények és alkalmazásuk eljárása
SG11201504410PA (en) 2012-12-07 2015-07-30 Chemocentryx Inc Diazole lactams
JP6306607B2 (ja) 2012-12-21 2018-04-04 ケモセントリックス，インコーポレイティド ジアゾールアミド
CN105008331B (zh) 2013-01-21 2018-02-16 阿勒根公司 作用于多个前列腺素受体、产生一般抗炎反应的化合物
HK1218249A1 (zh) 2013-01-25 2017-02-10 Rigel Pharmaceuticals, Inc. 用於治疗炎症性肠道疾病的化合物和方法
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
PT2964218T (pt) 2013-03-05 2018-03-26 Radikal Therapeutics Inc Pró-fármacos de derivados de nitróxido multifuncional e utilizações dos mesmos
PL2968218T3 (pl) 2013-03-13 2022-01-10 Neuroderm Ltd Skojarzenie do leczenia choroby parkinsona
FI2970101T4 (fi) 2013-03-14 2025-11-24 Alkermes Pharma Ireland Limited Fumaraattien aihiolääkkeitä ja niiden käyttö erilaisten sairauksien hoidossa
AU2014238478B2 (en) 2013-03-15 2018-07-19 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
WO2014179263A1 (en) 2013-04-30 2014-11-06 Allergan, Inc. Therapeutic agents
WO2014194209A1 (en) 2013-05-31 2014-12-04 Allergan, Inc. Substituted cyclopentenes as therapeutic agents
CA2917149C (en) 2013-07-02 2021-02-02 Cineole Corp., Llc Antimicrobial formulation comprising isoamyl hexanoates together with propanoic acid and/or isobutyric acid
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3035800B1 (en) 2013-08-22 2019-10-09 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN104546830B (zh) 2013-10-23 2018-03-09 善笙生物科技股份有限公司 来自牛樟芝菌丝体的化合物及混合物的用途
US9315486B2 (en) 2013-10-29 2016-04-19 Allergan, Inc. Therapeutic cyclopentanols, compositions thereof, and methods for use thereof
DK3063144T3 (da) 2013-11-01 2021-10-25 Boehringer Ingelheim Animal Health Usa Inc Antiparasitære og pesticid-isoxazolinforbindelser
WO2015073344A1 (en) 2013-11-14 2015-05-21 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EA029826B1 (ru) 2013-12-02 2018-05-31 Кемосентрикс, Инк. Соединения против ccr6
US9388153B2 (en) 2013-12-20 2016-07-12 Allergan, Inc. Secondary amines as therapeutic agents
US9365569B2 (en) 2014-01-27 2016-06-14 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
CN105960397B (zh) 2014-02-05 2020-09-04 默沙东公司 Cgrp-活性化合物的片剂制剂
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
PL3116475T3 (pl) 2014-03-13 2021-02-08 Neuroderm Ltd Kompozycje inhibitora dekarboksylazy dopa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
RU2016142145A (ru) 2014-04-22 2018-05-22 ТиЭксПи ФАРМА ГМБХ Пептидные аналоги с разветвленным аминокислотным зондом (зондами)
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
US9394273B2 (en) 2014-05-15 2016-07-19 Allergan, Inc. Therapeutic prostaglandin receptor agonists
CA2949511A1 (en) 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
WO2015179815A1 (en) 2014-05-22 2015-11-26 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
KR101636758B1 (ko) * 2014-05-30 2016-07-06 디씨에스이엔지 주식회사 회전속도비를 이용하여 회전체내 절삭툴을 제어할 수 있는 오비탈식 파이프 절삭장치
JP6588475B2 (ja) 2014-06-06 2019-10-09 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 治療用化合物としての新規のｅｐ４アゴニスト
US9908923B2 (en) 2014-06-11 2018-03-06 The Medical College Of Wisconsin, Inc. Monomeric CXCL121 peptide and methods of use thereof
WO2016009341A1 (en) 2014-07-14 2016-01-21 Radikal Therapeutics Inc. Thioredoxin mimetic prodrugs and uses thereof
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EP3190889B1 (en) 2014-09-03 2021-11-17 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2016044662A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CA2960876C (en) 2014-10-06 2024-02-13 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
CN107001360B (zh) 2014-12-02 2020-09-18 普拉纳生物技术有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物
CN112500301B (zh) 2014-12-09 2024-02-13 以西结·戈兰 放纵行为调节剂
CA2977127A1 (en) 2015-02-20 2016-08-25 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
EP3261639B1 (en) 2015-02-27 2022-08-24 Verseon International Corporation Substituted pyrazole compounds as serine protease inhibitors
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
RU2757417C2 (ru) 2015-05-19 2021-10-15 Йейл Юниверсити Композиции для лечения патологических состояний кальцификации и способы их применения
UY36683A (es) 2015-05-20 2016-12-30 Merial Inc Compuestos depsipeptídicos como anthelmínticos
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
DK3302527T3 (da) 2015-06-03 2020-03-30 Medical College Wisconsin Inc Manipuleret CCL20-låst-dimerpolypeptid
AU2016279804B2 (en) 2015-06-15 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
WO2016203314A1 (en) 2015-06-16 2016-12-22 University College Dublin, National University Of Ireland, Dublin Thromboxane receptor antagonists
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
NO346258B1 (en) 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
WO2017007835A1 (en) 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for nanoemulsion vaccine formulations
WO2017025951A1 (en) 2015-08-10 2017-02-16 Ramot At Tel-Aviv University Ltd. Pillararenes and uses thereof
WO2017077528A2 (en) 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
US10660884B2 (en) 2015-11-02 2020-05-26 University Of Rochester Phosphonate-chloroquine conjugates and methods using same
EP3371203B1 (en) 2015-11-02 2020-02-26 University Of Rochester Bortezomib conjugates and methods using same
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
EP3377105A4 (en) 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
US20170202821A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy
KR102799183B1 (ko) 2016-01-20 2025-04-21 케모센트릭스, 인크. 2-옥신돌 화합물
MX2018009662A (es) 2016-02-11 2018-09-11 Chevion Mordechai Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2017153977A1 (en) 2016-03-08 2017-09-14 Salzman Lovelace Investments, Ltd. Solid formulations of resolvins and uses thereof
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
US10036024B2 (en) 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
JP6548843B1 (ja) 2016-06-03 2019-07-24 ノバサイト インコーポレイテッド ポリマーリンカーおよびそれらの使用法
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
ES3041483T3 (en) 2016-07-11 2025-11-12 Contera Pharma As Pulsatile drug delivery system for treating morning akinesia
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
WO2018039508A1 (en) 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
US10653144B2 (en) 2016-10-14 2020-05-19 Boehringer Ingelheim Animal Health USA Inc. Pesticidal and parasiticidal vinyl isoxazoline compounds
US11021510B2 (en) 2016-11-03 2021-06-01 Laurence I. Wu Prodrugs of clofarabine
SG11201902944TA (en) 2016-11-07 2019-05-30 Arbutus Biopharma Corp Substituted pyridinone-containing tricyclic compounds, and methods using same
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
CA3044038A1 (en) 2016-11-16 2018-05-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc Method of treating focal segmental glomerulosclerosis
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
ES2926545T3 (es) 2016-12-14 2022-10-26 Intervet Int Bv Aminopirazoles como inhibidores selectivos de la quinasa Janus
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
WO2018191579A1 (en) 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections
DE202017002464U1 (de) 2017-05-09 2017-06-12 St. Lotus Biotech Corp. Pflanzliche Zusammensetzung zur Vorbeugung oder Linderung von ischämischem Schlaganfall
US11484543B2 (en) 2017-05-18 2022-11-01 The Rockefeller University Compositions and methods for diagnosing and treating diseases and disorders associated with mutant KCNJ5
JP2020527133A (ja) 2017-06-20 2020-09-03 インブリア ファーマシューティカルズ， インコーポレイテッド 心臓代謝の効率を高めるための組成物および方法
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
JP2020530850A (ja) 2017-08-14 2020-10-29 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 殺有害生物および殺寄生生物ピラゾール−イソキサゾリン化合物
EP3672936A4 (en) 2017-08-23 2021-05-19 Gavish-Galilee Bio Applications Ltd COMPOSITIONS AND METHODS OF TREATMENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASES
JP7453139B2 (ja) 2017-09-25 2024-03-19 ケモセントリックス，インコーポレイティド ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法
SG11202002975YA (en) 2017-10-11 2020-04-29 Chemocentryx Inc Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
WO2019104316A1 (en) 2017-11-27 2019-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, compositions, and methods for treating and/or preventing periodontal disease
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
CN111788184B (zh) 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
WO2019136370A2 (en) 2018-01-08 2019-07-11 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
WO2019141957A1 (en) 2018-01-19 2019-07-25 Cado Biotechnology Ivs N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
CN117643587A (zh) 2018-02-05 2024-03-05 深圳市原力生命科学有限公司 用于治疗癌症的杂二环羧酸
US11583545B2 (en) 2018-02-08 2023-02-21 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof
JP2021513553A (ja) 2018-02-13 2021-05-27 ビートルバング ファーマ リミテッド カンナビノイド誘導体並びにそのコンジュゲート及びその使用
JP7387616B2 (ja) 2018-02-22 2023-11-28 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン
US10982210B2 (en) 2018-03-02 2021-04-20 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
US11608336B2 (en) 2018-04-02 2023-03-21 Chemocentryx, Inc. Prodrugs of fused-bicyclic C5aR antagonists
EP3552605A1 (en) 2018-04-11 2019-10-16 Univerzita Palackého V Olomouchi Mcoppb for use as medicament
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
CA3101738A1 (en) 2018-05-29 2019-12-05 Cersci Therapeutics, Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374607A1 (en) 2018-06-08 2019-12-12 The Medical College Of Wisconsin, Inc. Methods of treating vascular leakage using cxcl12 peptides
MX2021000293A (es) 2018-07-09 2021-07-15 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos.
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
EP4497474A3 (en) 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
WO2020092136A1 (en) 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
EP3883648A1 (en) 2018-11-20 2021-09-29 Boehringer Ingelheim Animal Health USA Inc. Indazolylcyanoethylamino compound, compositions of same, method of making, and methods of using thereof
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
WO2020159588A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
BR112021018631A2 (pt) 2019-03-19 2021-11-23 Boehringer Ingelheim Animal Health Usa Inc Compostos anti-helmínticos de aza-benzotiofeno e aza-benzofurano
US11684652B2 (en) 2019-05-09 2023-06-27 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of acute lung injury
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
EP3980412B1 (en) 2019-06-06 2025-08-13 Merck Sharp & Dohme LLC 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
BR112022000113A2 (pt) 2019-07-08 2022-03-15 Activesite Pharmaceuticals Inc Processos para preparação de inibidores de calicreí-na de plasma
EP3996711A4 (en) 2019-07-10 2023-08-16 ChemoCentryx, Inc. Indanes as pd-l1 inhibitors
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
JP7681570B2 (ja) 2019-08-14 2025-05-22 ライジェル ファーマシューティカルズ， インコーポレイテッド サイトカイン放出症候群をブロック又は改善する方法
CR20220215A (es) 2019-10-16 2022-09-14 Chemocentryx Inc Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
KR20220088744A (ko) 2019-10-25 2022-06-28 머크 샤프 앤드 돔 코포레이션 Lrrk2 억제제로서의 n-(헤테로아릴) 퀴나졸린-2-아민 유도체, 제약 조성물 및 그의 용도
KR20220099989A (ko) 2019-11-08 2022-07-14 케모센트릭스, 인크. 보체 성분 c5a 수용체의 염 형태
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
US20210308117A1 (en) 2020-03-20 2021-10-07 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
IL296054A (en) 2020-03-27 2022-10-01 Aclaris Therapeutics Inc Oral preparations of the mk2 pathway inhibitor for the treatment of immune conditions
AU2021248942A1 (en) 2020-03-31 2022-11-17 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodies
IL297489A (en) 2020-04-23 2022-12-01 Aztherapies Inc Cellular ablation of hla-class i mhc
EP3901160A1 (en) 2020-04-25 2021-10-27 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
CA3176025A1 (en) 2020-04-24 2021-10-28 Nuvamid Sa Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
EP4143316A2 (en) 2020-04-27 2023-03-08 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
BR112022021155A2 (pt) 2020-04-30 2022-12-06 M Tobia Annette Composições e métodos para tratar tempestade de citocina
CN119410588A (zh) 2020-05-28 2025-02-11 阿茨治疗股份有限公司 用于治疗神经变性疾病的靶向髓鞘少突胶质细胞糖蛋白(mog)的基于car-treg的疗法
JP2023528822A (ja) 2020-05-29 2023-07-06 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性複素環式化合物
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
MX2023000447A (es) 2020-07-07 2023-04-20 Atxa Therapeutics Ltd Antagonista de receptor de tromboxano formulaciones.
US20230287031A1 (en) 2020-07-17 2023-09-14 Université De Bretagne Occidentale New glycolipids and use thereof as sk3 ion channel modulators
CA3190176A1 (en) 2020-07-29 2022-02-03 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022029275A1 (en) 2020-08-06 2022-02-10 Nuvamid Sa Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
EP4192475A1 (en) 2020-08-07 2023-06-14 Nuvamid SA Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity
WO2022034062A1 (en) 2020-08-12 2022-02-17 Txp Pharma Ag Exendin-4 peptide analogues
CA3198225A1 (en) 2020-10-13 2022-04-21 Betavive Ltd. Method and compounds for treating diabetes and associated metabolic diseases
GB202017251D0 (en) 2020-10-30 2020-12-16 Queens Univ Of Belfast Neurodegenerative treatment
GB202017255D0 (en) 2020-10-30 2020-12-16 Queens Univ Of Belfast Immunomodulatory agent
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11793807B2 (en) 2020-12-10 2023-10-24 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
US11730733B2 (en) 2020-12-10 2023-08-22 Imbria Pharmaceuticals, Inc. Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
US12076318B2 (en) 2020-12-10 2024-09-03 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
US11969422B2 (en) 2020-12-10 2024-04-30 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
CN117304242A (zh) 2020-12-18 2023-12-29 努瓦米德股份有限公司 烟酰胺单核苷酸衍生物及其在治疗和预防红细胞病症中的用途
CN116940350A (zh) 2021-02-08 2023-10-24 博施健康爱尔兰有限公司 预防、治疗或改善溃疡性结肠炎的阿米莫德
WO2022184685A1 (en) 2021-03-01 2022-09-09 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof for the treatment and/or prevention of long covid-19
EP4070799A1 (en) 2021-04-08 2022-10-12 Nuvamid SA Compositions for the improvement of sport performance
EP4079311B1 (en) 2021-04-20 2025-10-01 Nuvamid SA Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
EP4079310A1 (en) 2021-04-20 2022-10-26 Nuvamid SA Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
WO2022254425A1 (en) 2021-05-31 2022-12-08 Cannabotech Ltd. Compositions comprising a cannabinoid and uses thereof
WO2022263625A1 (en) 2021-06-17 2022-12-22 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
WO2022263676A1 (en) 2021-06-18 2022-12-22 University Of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
CA3227520A1 (en) 2021-08-02 2023-02-09 Laurent GARCON Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
WO2023023532A2 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
WO2023062545A1 (en) 2021-10-12 2023-04-20 Betavive Ltd. Peptides and fragments for treating diabetes and associated metabolic diseases
TW202423928A (zh) 2022-09-02 2024-06-16 美商默沙東有限責任公司 源自依克沙替康(exatecan)之拓樸異構酶-1抑制劑醫藥組合物及其用途
KR20250059489A (ko) 2022-09-06 2025-05-02 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 조현병 및 기타 신경정신장애 및 신경학적 장애의 치료를 위한 환각물질 포함 조합물
EP4608453A1 (en) 2022-10-25 2025-09-03 Merck Sharp & Dohme LLC Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
JP2025522671A (ja) 2022-12-14 2025-07-17 メルク・シャープ・アンド・ドーム・エルエルシー アウリスタチンリンカー－ペイロード、医薬組成物及びその使用
KR20250135296A (ko) 2023-01-20 2025-09-12 에픽스 테라퓨틱스 Mettl3 억제제로서의 피페리딘 유도체
AU2024239653A1 (en) 2023-03-17 2025-10-09 Atmosr Adenine derivatives as hsp90 inhibitors
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease
WO2025011733A1 (en) 2023-07-07 2025-01-16 Nuvamid Sa Nicotinamide mononucleotide and derivatives thereof and use thereof in the treatment and prevention of polycythemia
WO2025037248A1 (en) 2023-08-14 2025-02-20 Neurim Pharmaceuticals (1991) Ltd. Gal475 compositions and methods of use thereof
WO2025064408A1 (en) 2023-09-18 2025-03-27 The Broad Institute, Inc. Compositions and methods for treating cardiovascular disease
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
GB2636364A (en) 2023-12-07 2025-06-18 Aramune Tech Limited Arabinogalactan
WO2025134072A1 (en) 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
WO2025176994A1 (en) 2024-02-20 2025-08-28 Analytical Services For Art & Archaeology (Scotland) Ltd Composition and method of use
WO2025219976A1 (en) 2024-04-19 2025-10-23 Betavive Ltd. Peptides and fragments for treating diabetes and associated metabolic diseases
GB202405650D0 (en) 2024-04-22 2024-06-05 Royal College Surgeons Ireland Hdac6 protacs

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2211485A (en) * 1940-08-13 Effervescent acetyl salicylic acid
US536155A (en) * 1895-03-19 Pill or tablet
US2312381A (en) * 1940-10-24 1943-03-02 Frank J Bickenheuser Medicinal tablet
US3062715A (en) * 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
GB917456A (en) * 1958-10-30 1963-02-06 Casco Lab Inc Suppository composition and preparation thereof
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3136692A (en) * 1961-06-30 1964-06-09 Strong Cobb Arner Inc Effervescent composition containing polyvinylpyrrolidone
GB1093286A (en) * 1965-02-15 1967-11-29 Biorex Laboratories Ltd Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents
FR5391M (enExample) * 1965-11-04 1967-10-23
GB1123316A (en) * 1966-12-09 1968-08-14 Wynlit Pharmaceuticals Trust R Improvements in suppositories
US3495001A (en) * 1968-05-27 1970-02-10 Miles Lab Effervescent compositions of acetylsalicylic acid
US3887700A (en) * 1969-11-28 1975-06-03 Aspro Nicholas Ltd Analgesic formulations
US3764668A (en) * 1970-09-30 1973-10-09 Interx Research Corp Compositions of salts of salicylamide
US3676549A (en) * 1970-09-30 1972-07-11 Alza Corp Administration of alkali metal salts of salicylamide
GB1359614A (en) * 1971-04-06 1974-07-10 Dev Et De Rech Soc Fr De Method for the manufacture of effervescent tablets
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153214A (ja) * 1983-08-16 1986-03-17 ザ　ウエルカム　フアウンデ−シヨン　リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
US6639485B2 (en) 1999-12-09 2003-10-28 Murata Manufacturing Co., Ltd. Nonreciprocal circuit device and communication device using same
US6861922B2 (en) 2000-03-02 2005-03-01 Murata Manufacturing Co., Ltd. Nonreciprocal circuit device including two series resonant circuits having differing resonant frequencies
JP2018508941A (ja) * 2015-01-21 2018-03-29 ロッキード・マーティン・アドバンスト・エナジー・ストレージ・エルエルシーＬｏｃｋｈｅｅｄ Ｍａｒｔｉｎ Ａｄｖａｎｃｅｄ Ｅｎｅｒｇｙ Ｓｔｏｒａｇｅ， ＬＬＣ 電解液用の固体緩衝物質及びそれを利用したフロー電池

Also Published As

Publication number Publication date
IE810765L (en) 1981-10-25
GR73519B (enExample) 1984-03-09
PT72796A (fr) 1981-05-01
ES267593Y (es) 1983-11-16
DK152482B (da) 1988-03-07
ES267593U (es) 1983-05-16
DK184681A (da) 1981-10-26
IE51216B1 (en) 1986-11-12
US4265874A (en) 1981-05-05
ES510822A0 (es) 1983-06-16
EP0040899A3 (en) 1982-08-11
DK152482C (da) 1988-08-01
EP0040899A2 (en) 1981-12-02
ATE9267T1 (de) 1984-09-15
PT72796B (fr) 1982-03-30
JPH044293B2 (enExample) 1992-01-27
DE3165901D1 (en) 1984-10-18
NZ196561A (en) 1983-05-10
ES8307092A1 (es) 1983-06-16
EP0040899B1 (en) 1984-09-12

Similar Documents

Publication Publication Date Title
JPS56167617A (en) Permeation device
US4801093B1 (en) Push-nipple for medical sprayer
JPS5793065A (en) Permeation apparatus having hydrogel drive member
DE69731320D1 (de) Abgabevorrichtung für additive
EP0684796A4 (en) CONTAINER FOR BLOOD STORAGE AND METHOD OF USE.
ES8705240A1 (es) Dispositivo osmotico para la administracion controlada de unagente benefico a un ambiente de utilizacion
AU1926795A (en) Gas delivery apparatus and compositions for infusion
NZ290045A (en) Osmotic delivery device includes a fluid impermeable and fluid permeable portion and a head space spaced from an exit passageway in the device
ES8503499A1 (es) Dispositivo osmotico
ES257490U (es) Bolsa de inyeccion de fluido
ES288293U (es) Dispositivo para el equilibrado de la presion para contenedor de transporte.
UA7225A1 (uk) Дозуючий пристрій, розташований у колпачку аерозольної ємкості
ES8500753A1 (es) Un dispositivo parallamas para comprobar el retorno de llama en un sistema que contiene un gas a presion potencialmente detonable
ES2134908T3 (es) Difusor con brida y retenedor de camara de aire para recipiente a presion.
AU3160999A (en) Dispensing means
JPS5791773A (en) Method for sending paint to roller type painting apparatus under pressure
GB1157970A (en) Improvements in or relating to Aerosol Dispensers
EP0704229A3 (de) Verfahren und Vorrichtung zum impulsförmigen Austragen einer Flüssigkeit, insbesondere eines Feuerlöschmittels
SE9203096D0 (sv) Fyllbar brandslaeckare av hydropress-typ
SE8401339D0 (sv) Vetskeavskiljare i brensletank